Walleye Capital LLC Intercept Pharmaceuticals, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$11.23 - $19.59 $118,622 - $206,929	-10,563 Reduced 31.85%	22,600 $312,000
Q1 2022 May 16, 2022	BUY	$13.37 - $17.79 $443,389 - $589,969	33,163 New	33,163 $540,000
Q2 2021 Aug 16, 2021	SELL	$15.46 - $24.5 $381,490 - $604,562	-24,676 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$19.33 - $37.75 $246,979 - $482,331	-12,777 Reduced 34.11%	24,676 $570,000
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $586,124 - $1.02 Million	23,943 Added 177.22%	37,453 $925,000

Q3 2020 Nov 16, 2020	BUY	$39.09 - $53.44 $528,105 - $721,974	13,510 New	13,510 $560,000
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $4,351 - $10,681	-90 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$57.36 - $124.1 $5,162 - $11,169	90 New	90 $11,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.